10 FACE / SHUTTERSTOCK.COM
Lawyers have claimed that the latest ruling in Ariosa Diagnostics v Sequenom creates an “existential threat” to biomedical patents in the US, but is this really the case? LSIPR investigates.
There could be dire consequences for biomedicine and patent law as a whole—that’s one view of the latest ruling in Ariosa Diagnostics v Sequenom, which has sent shock waves through some sections of the US life sciences industry.
According to lawyers representing Sequenom, the molecular technology company whose patent was revoked in the case, the ruling creates an “existential threat” to patent protection for an array of meritorious inventions.
On June 12, a three-judge panel at the US Court of Appeals for the Federal Circuit affirmed that the patent, which protects a non-invasive method of testing a mother’s blood for genetic traits in her foetus, was invalid.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
Ariosa Diagnostics, Mayo, Myriad, DNA, patent, cffDNA